PHARMACEUTICAL 2022

Enliven Therapeutics Inc
Rank 146 of 471



PHARMACEUTICAL 2022

Enliven Therapeutics Inc
Rank 146 of 471

The relative strengths and weaknesses of Enliven Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enliven Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 101% points.The greatest weakness of Enliven Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 348%, being 73% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	92,696
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,210
Liabilities, Non-Current	406
Other Assets	700
Other Compr. Net Income	-20
Other Expenses	0
Other Liabilities	0
Other Net Income	58
Other Revenues	0
Property and Equipment	250
Research and Development	38,442
Selling, General and Administrative Expense	13,000

Output Variable	Value in 1000 USD
Assets	93,646
Liabilities	7,616
Expenses	51,442
Revenues	0
Stockholders Equity	86,030
Net Income	-51,384
Comprehensive Net Income	-51,394
BaseVar	76,391
ECR before LimitedLiability	269%
Economic Capital Ratio	348%